HER2/ERBB2 (erb-b2 receptor tyrosine kinase 2), a member of the epidermal growth factor receptor family, is amplified/overexpressed in 15–20% of breast cancers and associated with poor prognosis25. Here, EGFR is linked to breast carcinoma.